Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Boehringer Ingelheim Receives EC Clearance for Once-Daily Version of Parkinson's Therapy

  • The European Commission has sanctioned Boehringer Ingelheim’s prolonged-release, once-daily version of its Parkinson’s disease (PD) drug called Mirapexin®/Sifrol® (pramipexole). It is indicated for the treatment of early and advanced idiopathic PD.

    The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate-release tablet, which is taken three times daily.

    An NDA for the once-daily, extended-release formulation of pramipexole is under review with the FDA.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »